| Total | Rs671(−) | Rs671(+) | p | |||
---|---|---|---|---|---|---|---|
All | 105 | Â | 56 | Â | 49 | Â | Â |
Sex | |||||||
 Male | 89 | (85%) | 44 | (79%) | 45 | (92%) | 0.059 |
 Female | 16 | (15%) | 12 | (21%) | 4 | (8%) |  |
Age (years) | |||||||
 Median (IQR) | 69 |  | 69 |  | 69 |  | 0.835 |
 40–49 | 6 | (6%) | 4 | (7%) | 2 | (4%) | 0.970 |
 50–59 | 12 | (11%) | 6 | (11%) | 6 | (12%) |  |
 60–69 | 37 | (35%) | 20 | (36%) | 17 | (35%) |  |
 70–79 | 46 | (44%) | 24 | (43%) | 22 | (45%) |  |
 80–89 | 4 | (4%) | 2 | (4%) | 2 | (4%) |  |
Brinkman Index | |||||||
 < 100 | 14 | (13%) | 10 | (18%) | 4 | (8%) | 0.330 |
 < 1000 | 39 | (37%) | 19 | (34%) | 20 | (41%) |  |
 ≥ 1000 | 52 | (50%) | 27 | (48%) | 25 | (51%) |  |
Type of ICI (first dose) | |||||||
 Pembrolizumab | 45 | (43%) | 24 | (43%) | 21 | (43%) | 0.658 |
 Atezolizumab | 20 | (19%) | 9 | (16%) | 11 | (22%) |  |
 Nivolumab | 40 | (38%) | 23 | (41%) | 17 | (35%) |  |
Tumor histotype | |||||||
 Squamous cell carcinoma | 30 | (29%) | 19 | (34%) | 11 | (22%) | 0.176 |
 Adenocarcinoma | 64 | (61%) | 31 | (55%) | 33 | (67%) |  |
 Pleomorphic carcinoma | 5 | (5%) | 1 | (2%) | 4 | (8%) |  |
 Mesothelioma | 2 | (2%) | 2 | (4%) | 0 | (0%) |  |
 Othera | 4 | (4%) | 3 | (5%) | 1 | (2%) |  |
TNM classification | |||||||
 Stage III | 25 | (24%) | 15 | (27%) | 10 | (20%) | 0.148 |
 Stage IV | 51 | (49%) | 30 | (54%) | 21 | (43%) |  |
 Unknown | 29 | (28%) | 11 | (20%) | 18 | (37%) |  |
Treatment line | |||||||
 First-line | 41 | (39%) | 21 | (38%) | 20 | (41%) | 0.840 |
 Second-line | 31 | (30%) | 16 | (29%) | 15 | (31%) |  |
 Third-line and later | 33 | (31%) | 19 | (34%) | 14 | (29%) |  |
Chemotherapy with first ICI | |||||||
 No | 99 | (94%) | 52 | (93%) | 47 | (96%) | 0.683 |
 Yes | 6 | (6%) | 4 | (7%) | 2 | (4%) |  |
PD-L1 (+) ratio in cancer tissue | |||||||
 < 1% | 20 | (19%) | 5 | (9%) | 15 | (31%) | 0.012 |
 < 50% | 22 | (21%) | 13 | (23%) | 9 | (18%) |  |
 ≥ 50% | 48 | (46%) | 26 | (46%) | 22 | (45%) |  |
 Unassessed | 15 | (14%) | 12 | (21%) | 3 | (6%) |  |
EGFR mutation in cancer tissue | |||||||
  (−) | 81 | (77%) | 38 | (68%) | 43 | (88%) | 0.400 |
  (+) | 8 | (8%) | 5 | (9%) | 3 | (6%) |  |
 Unassessed | 16 | (15%) | 13 | (23%) | 3 | (6%) |  |
Neutrophil count in peripheral blood | |||||||
 Geometric mean (GSD) (/μL) | 4663 | (3134) | 4501 | (5167) | 4854 | (4808) | 0.456 |
 < 3500/μL | 29 | (28%) | 19 | (34%) | 10 | (20%) | 0.273 |
 < 5000/μL | 37 | (35%) | 19 | (34%) | 18 | (37%) |  |
 ≥ 5000/μL | 39 | (37%) | 18 | (32%) | 21 | (43%) |  |
Lymphocyte count in peripheral blood | |||||||
 Geometric mean (GSD) (/μL) | 1240 | (752) | 1141 | (1093) | 1362 | (1344) | 0.056 |
 < 1000/μL | 31 | (30%) | 19 | (34%) | 12 | (24%) | 0.151 |
 < 1500/μL | 39 | (37%) | 23 | (41%) | 16 | (33%) |  |
 ≥ 1500/μL | 35 | (33%) | 14 | (25%) | 21 | (43%) |  |